The function of the SAIP is to collaborate with NCI investigators in the development of mouse models, new molecular imaging probes for early detection and therapy, monitor tumors in vivo, and perform drug efficacy studies utilizing in vivo imaging techniques. In addition, the SAIP collaborates with the NCI Division of Cancer Treatment and Diagnosis (DCTD) Nanotechnology Characterization Laboratory (NCL) to analyze nanoplatforms as part of the cascade assay and assist DCTD initiatives in developing standards in small animal imaging, integrate imaging into drug development, and develop partnerships with industry for technology and drug development.
Quantitative analysis of many physiological and functional parameters, including anatomical and physiological tumor volumes, biodistribution, tumor vasculature and perfusion, tracer kinetics (pharmacokinetics), blood flow, tissue Doppler, internal radiation dosimetry, metabolic imaging, and cardiac function.
Technologies
The SAIP develops new acquisition and image analysis techniques based on the requirements of an imaging project.
Past developments included
Nuclear: PET/SPECT/CT (Mediso NanoScan)
Optical: Bioluminescence and Fluorescence (IVIS Spectrum PerkinElmer) and Short Wavelength Infrared (SWIR)
MRI: 3T MRI (Ingenia Elition Philips Medical Systems)
Ultrasound: Vevo 2100 and F2 (FujiFilm VisualSonics)
HyperPolarizer (13C-Pyruvate): HyperSense (Oxford Instruments)
Services are available to all NCI investigators located at the Frederick and Bethesda campuses. Excess capacity can be made available to other NIH Investigators on a case-by-case basis. To request services from this NCI core facility, you must submit an SAIP imaging submission: https://ncifrederick.cancer.gov/Lasp/saip/Wizard/Requests/Step1Wizard.aspx. After the ACUC approves the imaging submission, a NAS (https://ncifrederick.cancer.gov/services/accessioning/) is submitted.